Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14440883 | 0.83 | HPGD (0.47) | L3MBTL1MEN1KMT2ATDP1HPGD | |
| SCHEMBL12389242 | 0.81 | ATM (0.45) | L3MBTL1MEN1KMT2ATDP1HPGD | |
| SCHEMBL20381544 | 0.80 | CYP2D6 (0.42) | MEN1KMT2AHPGDSMN1; SMN2NPC1 | |
| SCHEMBL20381566 | 0.79 | ALDH1A1 (0.35) | MEN1KMT2AHPGDSMN1; SMN2NPC1 | |
| SCHEMBL18747345 | 0.77 | HPGD (0.41) | L3MBTL1MEN1KMT2ATDP1HPGD | |
| SCHEMBL879545 | 0.74 | HPGD (0.50) | L3MBTL1MEN1KMT2ATDP1HPGD | |
| SCHEMBL31007038 | 0.73 | ALDH1A1 (0.59) | L3MBTL1MEN1KMT2ATDP1HPGD | |
| SCHEMBL13450960 | 0.72 | KMT2A (0.52) | L3MBTL1MEN1KMT2ATDP1HPGD | |
| SCHEMBL1220310 | 0.72 | KMT2A (0.52) | L3MBTL1MEN1KMT2ATDP1HPGD | |
| SCHEMBL12335991 | 0.72 | L3MBTL1 (0.48) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMC1, PSMB11 | L3MBTL1 493/4885MEN1 3370/4885KMT2A 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.